NO943888L - Farmasöytisk preparat - Google Patents

Farmasöytisk preparat

Info

Publication number
NO943888L
NO943888L NO943888A NO943888A NO943888L NO 943888 L NO943888 L NO 943888L NO 943888 A NO943888 A NO 943888A NO 943888 A NO943888 A NO 943888A NO 943888 L NO943888 L NO 943888L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
antiulcus
activity
carboxylic acid
pharmaceutical composition
Prior art date
Application number
NO943888A
Other languages
English (en)
Norwegian (no)
Other versions
NO943888D0 (no
Inventor
Nobuyuki Takechi
Akihiro Nagai
Naoru Hamaguchi
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO943888D0 publication Critical patent/NO943888D0/no
Publication of NO943888L publication Critical patent/NO943888L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO943888A 1993-10-15 1994-10-14 Farmasöytisk preparat NO943888L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25865593 1993-10-15

Publications (2)

Publication Number Publication Date
NO943888D0 NO943888D0 (no) 1994-10-14
NO943888L true NO943888L (no) 1995-04-18

Family

ID=17323272

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943888A NO943888L (no) 1993-10-15 1994-10-14 Farmasöytisk preparat

Country Status (9)

Country Link
US (1) US5536735A (fi)
EP (1) EP0649655A1 (fi)
KR (1) KR950010895A (fi)
BR (1) BR9404114A (fi)
CA (1) CA2118195A1 (fi)
FI (1) FI944832A (fi)
HU (1) HUT70565A (fi)
NO (1) NO943888L (fi)
TW (1) TW280770B (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
EP0880969A1 (en) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
US7230014B1 (en) * 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
CA2419067C (en) * 2000-08-18 2008-12-23 Takeda Chemical Industries, Ltd. Injectable composition comprising benzimidazole compound and strong alkali
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
WO2002051411A1 (fr) * 2000-12-22 2002-07-04 Yamanouchi Pharmaceutical Co., Ltd. Injections de famotidine
PT1355910E (pt) 2001-01-25 2011-03-24 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulação de compostos do ácido borónico
US20020182237A1 (en) * 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1H-피롤-1-릴)-1H-벤즈이미다졸 또는 이의 Nа염을 함유하는주사제의 제조방법
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1648417A4 (en) * 2003-07-18 2010-01-20 Santarus Inc PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF GASTROINTESTINAL ACIDITY RELATED DISORDERS
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20090137633A1 (en) * 2003-08-18 2009-05-28 Bakulesh Mafatlal Khamar Stable pharmaceutical composition of rabeprazole
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US20070014875A1 (en) * 2003-11-05 2007-01-18 Bajaj Mannalal R Novel drug delivery system for proton pump inhibitors and process thereof
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
CN101795694B (zh) * 2007-09-04 2012-10-10 明治制果药业株式会社 注射剂、注射液和注射用试剂盒制剂
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
GB1592053A (en) * 1976-12-16 1981-07-01 Norbrook Lab Ltd Oxytetracycline compositions
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
US4490533A (en) * 1980-12-22 1984-12-25 Merck & Co., Inc. Aminoalkyl pyridine derivatives
US4472409A (en) 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US4738975A (en) 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
CA1276017C (en) 1986-02-13 1990-11-06 Takeda Chemical Industries, Ltd. Sulfenamide derivatives and their production
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
FI96860C (fi) 1987-06-17 1996-09-10 Eisai Co Ltd Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi
JPH01139528A (ja) * 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
DK399389A (da) * 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
CA2053527C (en) 1990-10-17 2002-03-12 Takashi Sohda Pyridine derivatives, their production and use
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola

Also Published As

Publication number Publication date
CA2118195A1 (en) 1995-04-16
HUT70565A (en) 1995-10-30
US5536735A (en) 1996-07-16
TW280770B (fi) 1996-07-11
NO943888D0 (no) 1994-10-14
BR9404114A (pt) 1995-06-13
FI944832A0 (fi) 1994-10-14
HU9402974D0 (en) 1995-02-28
FI944832A (fi) 1995-04-16
EP0649655A1 (en) 1995-04-26
KR950010895A (ko) 1995-05-15

Similar Documents

Publication Publication Date Title
NO943888L (no) Farmasöytisk preparat
NO974071D0 (no) Orale, farmasöytiske doseringsformer omfattende en protonpumpeinhibitor og et syrenöytraliserende middel eller alginat
NO983376D0 (no) Sulfonerte aminosyrederivater og metalloproteinase inhibitorer inneholdende de samme
HRP20020182B1 (en) Benzamide formulation with histone deacetylase inhibitor activity
DK0814840T3 (da) Orale farmaceutiske doseringsformer, der omfatter en protonpumpeinhibitor og et prokinetisk middel
NO901399D0 (no) Aminosyrederivater.
NO892407D0 (no) Aminosyrederivater.
DK617388D0 (da) Substituerede carboxylsyrederivater, deres fremstiilling og anvendelse som fungicider
NO933455D0 (no) Bis-naftalimider som inneholder aminosyreavledete linkere, for anvendelse som antikreftmidler
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
NO20013675D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer
FI955130A0 (fi) L-aminohappo-oksidaasi
DE68913137D1 (de) Carbonsäure-Derivate.
NO951147D0 (no) Substituerte heterocykliske karboksylsyreamidestere, deres fremstilling og deres anvendelse som legemiddel
NO983464L (no) Buffersystemer for stabilisering av farmas°ytiske preparater
NO991994D0 (no) Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriks-metalloproteaseinhibitorer
DK0799223T3 (da) Piperidineddikesyrederivater til anvendelse som fibrinogenantagonistmidler
NO922167L (no) Aminodukter som korrosjonshemmere
NO901533D0 (no) Aminosyrederivater.
DE69625230T2 (de) Thrombininhibitoren
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
DK0410358T3 (da) Aromatiske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler
NO940844D0 (no) Farmasöytisk aktive hydroksykarboksylsyrederivater
FI962264A (fi) Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
ES2156877T3 (es) Anilidas de acidos cicloalquilcarboxilicos.